MX2017007955A - Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. - Google Patents

Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.

Info

Publication number
MX2017007955A
MX2017007955A MX2017007955A MX2017007955A MX2017007955A MX 2017007955 A MX2017007955 A MX 2017007955A MX 2017007955 A MX2017007955 A MX 2017007955A MX 2017007955 A MX2017007955 A MX 2017007955A MX 2017007955 A MX2017007955 A MX 2017007955A
Authority
MX
Mexico
Prior art keywords
azepine
dipropyl
carboxamide
carbonyl
phenyl
Prior art date
Application number
MX2017007955A
Other languages
English (en)
Inventor
Hon-Wah Man
Li Ying
D Fitzpatrick Timothy
Frank Anthony
Lu Xiaoling
G Beauchamps Marie
C Ferretti Antonio
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2017007955A publication Critical patent/MX2017007955A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan composiciones que incluyen las formas cristalinas de (lE, 4E)-2-amino-N,N-dipropil-8-(4-(pirrolid ina-1-carbonil)fenil)-3H-benzo[b]azepina-4-carboxamida ("Compuesto A"), métodos para producir las formas cristalinas y métodos para usar las formas cristalinas para el tratamiento de enfermedades que incluyen, por ejemplo, cáncer; En la presente se proporcionan formas cristalinas del compuesto que tiene la fórmula (I); (ver Fórmula) ((1E, 4E)-2-amino-N; N-dipropil-8-(4-(pirrolidina-1-carbonil)fenil)-3Hbenzo[b]azepina- 4-carboxamida ("Compuesto A")); la forma cristalina puede ser una forma cristalina no solvatada o solvatada del compuesto de la fórmula (I).
MX2017007955A 2014-12-16 2015-12-15 Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. MX2017007955A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092764P 2014-12-16 2014-12-16
PCT/US2015/065755 WO2016100302A2 (en) 2014-12-16 2015-12-15 Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof

Publications (1)

Publication Number Publication Date
MX2017007955A true MX2017007955A (es) 2018-02-19

Family

ID=56127832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007955A MX2017007955A (es) 2014-12-16 2015-12-15 Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.

Country Status (12)

Country Link
US (2) US20190100512A1 (es)
EP (1) EP3233088A4 (es)
JP (2) JP6707088B2 (es)
KR (1) KR20170118700A (es)
AU (1) AU2015362720B2 (es)
BR (1) BR112017012646A2 (es)
CA (1) CA2970358A1 (es)
EA (1) EA201791346A1 (es)
IL (1) IL252744A0 (es)
MX (1) MX2017007955A (es)
SG (1) SG11201704791WA (es)
WO (1) WO2016100302A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791346A1 (ru) 2014-12-16 2018-01-31 Селджин Корпорейшн ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
SG10202110183VA (en) 2017-03-15 2021-10-28 Silverback Therapeutics Inc Benzazepine compounds, conjugates, and uses thereof
CN109320456A (zh) * 2018-11-16 2019-02-12 天津商业大学 新晶型的抗肿瘤化合物及其制备方法和含其的组合物
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
MXPA02006660A (es) 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
DK2313111T3 (da) * 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-lignende receptoragonistformuleringer og anvendelse deraf
WO2010054215A1 (en) * 2008-11-06 2010-05-14 Ventirx Pharmaceuticals, Inc. Methods of synthesis of benzazepine derivatives
CN103237549A (zh) * 2010-10-01 2013-08-07 帆德制药股份有限公司 过敏性疾病的治疗方法
EA201791346A1 (ru) 2014-12-16 2018-01-31 Селджин Корпорейшн ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ

Also Published As

Publication number Publication date
EP3233088A2 (en) 2017-10-25
WO2016100302A2 (en) 2016-06-23
WO2016100302A3 (en) 2016-09-15
JP6707088B2 (ja) 2020-06-10
US10604510B2 (en) 2020-03-31
JP2017537962A (ja) 2017-12-21
US20190100512A1 (en) 2019-04-04
BR112017012646A2 (pt) 2018-01-02
JP2020079261A (ja) 2020-05-28
KR20170118700A (ko) 2017-10-25
EP3233088A4 (en) 2018-09-19
IL252744A0 (en) 2017-08-31
AU2015362720A1 (en) 2017-07-06
AU2015362720B2 (en) 2019-11-21
CA2970358A1 (en) 2016-06-23
SG11201704791WA (en) 2017-07-28
US20200002316A1 (en) 2020-01-02
EA201791346A1 (ru) 2018-01-31

Similar Documents

Publication Publication Date Title
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
ZA201701299B (en) Glycosidase inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MY181898A (en) Heterocyclic compounds and uses thereof
MX2016011992A (es) Derivados de piperidina-diona.
MX2015012431A (es) Pirrol amida como inhibidores.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
AU2015352440B2 (en) Compounds
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
WO2018039077A8 (en) Therapeutic compounds
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
GEP20186879B (en) Cycloalkyl-linked diheterocycle derivatives
MX2015013048A (es) Forma cristalina de un compuesto ansiolitico.
WO2018211324A8 (en) Prodrugs for the treatment of disease
PH12017500492A1 (en) Crystalline bace inhibitors
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
FG Grant or registration